Quarterly sales
- Sales: €194.3 million, up 8.8% at constant exchange rates1
- Continued strong growth in Asia (+26.8% at constant exchange rates) and the Americas (+20.1% at constant exchange rates); the EMEA region (-6.2% at constant exchange rates) was punctually impacted by the reform in the supply of contrast agents in France.
Confirmation of annual targets
- Sales: growth expected to exceed 8% on a like-for-like basis and at constant exchange rates
- Profitability: return of the restated EBITDA margin2to a higher level than in 2021 (14.4%).
Villepinte, April 25, 2024, 5:45 pm: Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, announces its sales for the1st fiscal quarter. At March 31, 2024, Group sales amounted to 194.3 million euros (M€), up 7.6% on the same period in 2023. Taking into account an unfavorable currency effect of €2.2 million, largely related to Asian currencies, sales at TCC1 were up 8.8% over the period.
